Nuclear Medicine Market Share Driven by Rising Cancer Diagnostics, Targeted Radiopharmaceutical Therapies, and Advanced Molecular Imaging | Valuates Reports

Nuclear Medicine Market Size
The global Nuclear Medicine market was valued at US$ 7224 million in 2025 and is anticipated to reach US$ 11830 million by 2032, at a CAGR of 7.4% from 2026 to 2032.

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-3I2814/Global_Nuclear_Medicine_Market_Insights_and_Forecast_to_2028

The Nuclear Medicine Market continues to expand as healthcare systems increasingly adopt molecular imaging and targeted radiopharmaceutical therapies to improve disease diagnosis, treatment planning, and patient management. Growing prevalence of cancer, cardiovascular disorders, neurological diseases, and endocrine conditions is driving sustained market growth by increasing demand for highly sensitive diagnostic imaging and precision therapeutic solutions. Nuclear medicine plays a critical role in modern healthcare by enabling clinicians to visualize physiological processes, detect diseases at earlier stages, and deliver targeted radiation therapy with greater precision. Market trends are being shaped by continuous advancements in positron emission tomography (PET), single-photon emission computed tomography (SPECT), hybrid imaging technologies, novel radiopharmaceutical development, and theranostic approaches that integrate diagnosis and therapy within a single clinical pathway. Expanding healthcare infrastructure, increased investment in cyclotron facilities and radioisotope production, and growing adoption of personalized medicine are further contributing to overall market size. Regulatory support for innovative radiopharmaceuticals, improved reimbursement policies in several regions, and ongoing clinical research into new radioactive tracers continue strengthening industry adoption. These developments support sustained market growth, expand market share across diagnostic and therapeutic applications, and contribute to a favorable long-term market forecast for the Nuclear Medicine Market.

The market is segmented into diagnostic nuclear medicine and therapeutic nuclear medicine. Diagnostic nuclear medicine currently accounts for the largest market share due to its widespread use in disease detection, staging, treatment monitoring, and functional imaging across hospitals and diagnostic centers worldwide. PET and SPECT imaging procedures are routinely utilized to evaluate oncology, cardiology, neurology, and endocrine disorders, making diagnostic radiopharmaceuticals an essential component of modern clinical practice. Therapeutic nuclear medicine is widely recognized as the fastest-growing segment, driven by increasing adoption of targeted radionuclide therapies for cancer treatment and expanding clinical use of theranostic approaches. Advances in radioligand therapy, peptide receptor radionuclide therapy (PRRT), and prostate-specific membrane antigen (PSMA)-targeted therapies are significantly expanding the therapeutic role of nuclear medicine. Ongoing research into new radioisotopes and targeted treatment agents continues strengthening clinical adoption. Market trends emphasize precision medicine, personalized treatment planning, next-generation radiopharmaceutical development, and improved production capabilities, supporting continued market growth while expanding market share across both diagnostic and therapeutic segments.

Among application segments, oncology represents the largest market share within the Nuclear Medicine Market. The increasing global burden of cancer, combined with the growing use of PET imaging for diagnosis, staging, treatment response evaluation, and disease monitoring, continues driving strong demand for nuclear medicine procedures. In addition, targeted radiopharmaceutical therapies have become increasingly important for selected cancer indications, further strengthening oncology's leadership within the market. Cardiology also represents a major application segment, where nuclear imaging is widely used to evaluate myocardial perfusion, cardiac function, and coronary artery disease. Thyroid applications remain highly significant due to the long-established clinical use of radioactive iodine for both diagnostic evaluation and treatment of thyroid disorders, including differentiated thyroid cancer and hyperthyroidism. The "Others" category includes neurology, orthopedics, nephrology, infectious diseases, and additional clinical specialties where molecular imaging supports accurate diagnosis and treatment planning. Market trends indicate growing integration of artificial intelligence-assisted image analysis, quantitative imaging techniques, hybrid PET/CT and PET/MRI systems, and precision radiopharmaceutical therapies, contributing to sustained market growth and expanding market share across multiple therapeutic areas.

The competitive landscape includes globally recognized healthcare companies, radiopharmaceutical manufacturers, imaging technology providers, and pharmaceutical organizations that continue driving innovation throughout the Nuclear Medicine Market. GE Healthcare remains one of the leading providers of molecular imaging systems, PET and SPECT technologies, and radiopharmaceutical solutions supporting diagnostic nuclear medicine worldwide. Siemens Healthineers continues advancing hybrid imaging platforms, digital imaging technologies, and molecular imaging innovations that improve diagnostic accuracy and clinical efficiency. Novartis has established a strong position in therapeutic nuclear medicine through its radioligand therapy portfolio targeting specific cancer indications. Curium Pharma is one of the leading manufacturers of nuclear medicine products, supplying diagnostic and therapeutic radiopharmaceuticals across global healthcare markets. Cardinal Health plays a significant role in the production and distribution of radiopharmaceuticals through its extensive nuclear pharmacy network. Lantheus specializes in diagnostic imaging agents and radiopharmaceutical technologies, while Jubilant Pharma supports global nuclear medicine through radioisotope manufacturing and radiopharmaceutical production. Bracco Imaging, Bayer, Eli Lilly, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, and Yantai Dongcheng continue expanding capabilities in imaging agents, radiopharmaceutical manufacturing, pharmaceutical development, and isotope production. These prominent market participants continue strengthening their competitive positions through investments in research and development, production capacity expansion, strategic acquisitions, clinical trials, advanced manufacturing technologies, and international distribution networks. Their innovation continues shaping competitive dynamics while supporting long-term market growth and expanding market share.

North America currently holds the largest market share in the Nuclear Medicine Market, supported by advanced healthcare infrastructure, widespread availability of PET and SPECT imaging systems, strong reimbursement frameworks, and substantial investment in oncology and precision medicine. The United States remains the largest regional market due to extensive adoption of molecular imaging technologies, robust radiopharmaceutical research, and the presence of leading healthcare companies and nuclear pharmacy networks. Europe also maintains a substantial market share, driven by advanced healthcare systems, expanding use of targeted radionuclide therapies, and ongoing investment in diagnostic imaging across Germany, France, the United Kingdom, Italy, the Nordic countries, and other European markets. Asia-Pacific is expected to experience the fastest market growth as healthcare infrastructure expands, cancer incidence increases, and governments invest in advanced diagnostic imaging, radioisotope production, and precision medicine across China, Japan, South Korea, India, Australia, and other regional markets. Latin America and the Middle East & Africa are also witnessing gradual market expansion as access to nuclear medicine technologies improves and investment in specialized healthcare facilities continues. Looking ahead, the market forecast remains highly favorable as next-generation radiopharmaceuticals, theranostics, artificial intelligence-assisted imaging, targeted radionuclide therapies, advanced isotope production technologies, and personalized oncology continue transforming clinical practice. Continued investment in molecular imaging infrastructure, radioisotope manufacturing, precision medicine, and innovative therapeutic development is expected to shape future market trends, strengthen market growth, expand market size, and support sustained market share development across the global Nuclear Medicine Market.

Segment by Type

• Diagnostic Nuclear Medicine
• Therapeutic Nuclear Medicine

Segment by Application

• Oncology
• Thyroid
• Cardiology
• Others

By Company

Cardinal Health, GE Healthcare, Jubilant Pharma, Novartis, Curium Pharma, SIEMENS, Lantheus, Bracco Imaging, Bayer, Eli Lilly, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Yantai Dongcheng

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-3I2814/global-nuclear-medicine

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.